English

• 10 May, 2023
  Bulletin from the 2023 Annual General Meeting of Spago Nanomedical AB
• 9 May, 2023
  Spago Nanomedical interim report January-March 2023
• 4 May, 2023
  Presentation of Spago Nanomedical’s clinical phase IIa study in endometriosis at the 15th World Congress of Endometriosis
• 5 Apr, 2023
  Notice to Annual General Meeting of Spago Nanomedical AB (publ)
• 4 Apr, 2023
  The nomination committee proposes changes to the board of Spago Nanomedical for increased commercial focus
• 29 Mar, 2023
  Spago Nanomedical publishes the annual report for 2022
• 2 Feb, 2023
  Spago Nanomedical year-end report January-December, 2022
• 10 Jan, 2023
  Spago Nanomedical publishes scientific paper on positive preclinical data with Tumorad® as treatment of solid tumors
• 23 Dec, 2022
  Spago Nanomedical terminates liquidity guarantee
• 8 Dec, 2022
  First patient dosed in Spago Nanomedical’s endometriosis Phase IIa clinical study